Hansen Medical (HNSN) Misses Q3 EPS by 3c

Hansen Medical (NASDAQ: HNSN) reported Q3 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $5.7 million.

"During the third quarter, the Company expanded the body of clinical evidence for both the Magellan" Robotic System and the Sensei Robotic System as demonstrated by the results from the Barts Health NHS Trust study, the Imperial College study, and the first robot-assisted Uterine Fibroid Embolization procedure in the U.S.," said Cary Vance, Hansen Medical's Chief Executive Officer. "We believe demonstrating the breadth of capabilities of our robotic platforms through clinical validation will lead to optimal user experiences, increased utilization, and a higher value proposition."

For earnings history and earnings-related data on Hansen Medical (HNSN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Cisco rating cut at HSBC as analyst sees a lack of catalysts